Table 3

Family-based associations between CYP3A4 and CYP3A5 haplotypes and risk of prostate cancer among cases and sibling controls

Haplotype (CYP3A4/CYP3A5)ORs, 95% CIs, Pa
No StratificationStratified by disease aggressivenessb
LowHigh
All Subjects
 *1A/*31.0 (referent)1.01.0
 *1A/*10.90 (0.60–1.34), 0.600.62 (0.33–1.16), 0.131.17 (0.70–1.98), 0.55
 *1B/*10.65 (0.41–1.02), 0.060.22 (0.09–0.53), 0.00071.05 (0.60–1.82), 0.87
 *1B/*32.91 (1.36–6.23), 0.0064.51 (0.64–31.74), 0.133.15 (1.18–8.37), 0.02
Caucasians
 *1A/*31.01.01.0
 *1A/*10.76 (0.48–1.21), 0.250.62 (0.31–1.25), 0.180.92 (0.51–1.65), 0.77
 *1B/*10.76 (0.44–1.33), 0.340.07 (0.01–0.51), 0.0091.80 (0.95–3.43), 0.07
 *1B/*32.36 (0.85–6.54), 0.103.93 (0.47–32.82), 0.214.18 (0.71–24.79), 0.11
African-Americans
 *1A/*31.01.01.0
 *1A/*11.24 (0.49–3.18), 0.652.49 (0.29–21.1), 0.400.83 (0.16–4.19), 0.82
 *1B/*10.63 (0.26–1.56), 0.321.80 (0.12–28.0), 0.680.38 (0.09–1.54), 0.17
 *1B/*34.08 (1.35–12.4), 0.01 c 3.05 (1.22–7.61), 0.02
  • a Adjusted for age.

  • b Cases and their brothers stratified by tumor aggressiveness of affected brother. Low aggressiveness: Gleason <7, and T category <T2c. High aggressiveness: Gleason ≥7, or T category ≥T2c.

  • c Extremely unstable results due to small sample size.